JP2023549675A - 呼吸器疾患に関連する状態の治療および予防 - Google Patents
呼吸器疾患に関連する状態の治療および予防 Download PDFInfo
- Publication number
- JP2023549675A JP2023549675A JP2023526000A JP2023526000A JP2023549675A JP 2023549675 A JP2023549675 A JP 2023549675A JP 2023526000 A JP2023526000 A JP 2023526000A JP 2023526000 A JP2023526000 A JP 2023526000A JP 2023549675 A JP2023549675 A JP 2023549675A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- disease
- antigen
- cases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Otolaryngology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063108980P | 2020-11-03 | 2020-11-03 | |
| US63/108,980 | 2020-11-03 | ||
| PCT/US2021/057825 WO2022098701A1 (en) | 2020-11-03 | 2021-11-03 | Treatment and prevention of conditions associated with respiratory diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023549675A true JP2023549675A (ja) | 2023-11-29 |
| JP2023549675A5 JP2023549675A5 (cg-RX-API-DMAC10.html) | 2024-11-12 |
Family
ID=81458208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023526000A Pending JP2023549675A (ja) | 2020-11-03 | 2021-11-03 | 呼吸器疾患に関連する状態の治療および予防 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250195638A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4240329A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023549675A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230104640A (cg-RX-API-DMAC10.html) |
| CN (2) | CN116669708A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021373711A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3196661A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022098701A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116669708A (zh) * | 2020-07-22 | 2023-08-29 | 休斯敦大学系统 | 呼吸系统疾病相关病症的治疗和预防 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3471778A4 (en) * | 2016-06-20 | 2020-02-19 | The Regents of The University of Michigan | COMPOSITIONS AND METHOD FOR DELIVERING BIOMACROMOLECOLIC ACTIVE SUBSTANCES |
| CN106667914B (zh) * | 2017-03-13 | 2022-02-01 | 杭州星鳌生物科技有限公司 | 靶向脂质体-环二核苷酸的组成、制备方法及其在抗肿瘤中的应用 |
| CN106727331B (zh) * | 2017-03-13 | 2022-02-01 | 杭州星鳌生物科技有限公司 | 免疫脂质体-环二核苷酸的组成、制备方法及其在抗肿瘤中的应用 |
| KR101982710B1 (ko) * | 2017-03-17 | 2019-05-28 | 주식회사 큐라티스 | 스팅 작용자를 포함하는 면역항원보강제 및 백신 조성물 |
| TW202003032A (zh) * | 2018-03-23 | 2020-01-16 | 美商科迪亞克生物科學公司 | 包含s t i n g 促效劑之胞外囊泡 |
| CN111187354B (zh) * | 2020-02-20 | 2020-11-27 | 北京新创生物工程有限公司 | 新型冠状病毒(SARS-CoV-2)IgM/IgG抗体检测试剂盒 |
| CN111303254A (zh) * | 2020-02-20 | 2020-06-19 | 北京新创生物工程有限公司 | 新型冠状病毒(SARS-CoV-2)抗原检测试剂盒 |
| CN113456810A (zh) * | 2020-03-30 | 2021-10-01 | 杭州星鳌生物科技有限公司 | 一种新型抗新冠病毒治疗性疫苗及其制备方法和应用 |
| CN116669708A (zh) * | 2020-07-22 | 2023-08-29 | 休斯敦大学系统 | 呼吸系统疾病相关病症的治疗和预防 |
-
2021
- 2021-07-22 CN CN202180064648.3A patent/CN116669708A/zh active Pending
- 2021-11-03 CA CA3196661A patent/CA3196661A1/en active Pending
- 2021-11-03 KR KR1020237017850A patent/KR20230104640A/ko active Pending
- 2021-11-03 AU AU2021373711A patent/AU2021373711A1/en active Pending
- 2021-11-03 US US18/034,312 patent/US20250195638A1/en active Pending
- 2021-11-03 JP JP2023526000A patent/JP2023549675A/ja active Pending
- 2021-11-03 WO PCT/US2021/057825 patent/WO2022098701A1/en not_active Ceased
- 2021-11-03 CN CN202180089023.2A patent/CN116806146A/zh active Pending
- 2021-11-03 EP EP21889949.0A patent/EP4240329A4/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| BIORXIV, JPN6025034892, 23 July 2020 (2020-07-23), pages 1 - 31, ISSN: 0005670468 * |
| VIRUSES, vol. 12, 254, JPN6025034891, 25 February 2020 (2020-02-25), pages 1 - 15, ISSN: 0005670469 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3196661A1 (en) | 2022-05-12 |
| KR20230104640A (ko) | 2023-07-10 |
| EP4240329A1 (en) | 2023-09-13 |
| WO2022098701A1 (en) | 2022-05-12 |
| EP4240329A4 (en) | 2024-11-27 |
| CN116806146A (zh) | 2023-09-26 |
| AU2021373711A1 (en) | 2023-06-08 |
| AU2021373711A9 (en) | 2024-08-01 |
| US20250195638A1 (en) | 2025-06-19 |
| CN116669708A (zh) | 2023-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mendez-Gomez et al. | RNA aggregates harness the danger response for potent cancer immunotherapy | |
| US20230270845A1 (en) | Treatment and prevention of conditions associated with respiratory diseases | |
| US10251922B2 (en) | Newcastle disease viruses and uses thereof | |
| US8809290B2 (en) | Methods and compositions to generate and control the effector profile of T cells by simultaneous loading and activation of selected subsets of antigen presenting cells | |
| Lee et al. | A booster dose of Delta× Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants | |
| TW202146435A (zh) | 含有病原性抗原及免疫刺激物之組合物 | |
| CN111163758A (zh) | 具有记忆功能的t细胞或b细胞的增强剂、恶性肿瘤复发抑制剂、以及对t细胞或b细胞诱导记忆功能的诱导剂 | |
| Cao et al. | Inside-out assembly of viral antigens for the enhanced vaccination | |
| Wang et al. | IL-7 promotes mRNA vaccine-induced long-term immunity | |
| Giovannoni et al. | Retargeted oncolytic viruses engineered to remodel the tumor microenvironment for glioblastoma immunotherapy | |
| US20250195638A1 (en) | Treatment and prevention of conditions associated with respiratory diseases | |
| AU2024236982A1 (en) | Mutants of a ligand-dependent corepressor (lcor) and uses thereof | |
| CN112423786B (zh) | 用于病毒感染的细胞佐剂 | |
| Li et al. | CpG 1018 augments mRNA vaccine-induced anti-tumor immunity by potentiating CD8+ T cell responses | |
| US20230233674A1 (en) | Intranasal vaccines and therapeutics for respiratory diseases | |
| US20230390370A1 (en) | Neoantigen vaccines for pancreatic cancer | |
| Slamanig | Development of an intranasal SARS-CoV-2 vaccine | |
| Jenkins | Local Priming Of Long-Lived Tcf1+ Memory Cd8+ T Cell Responses In The Spleen During Influenza Virus Infection By Lung Derived Migratory Dendritic Cells | |
| Abraş | Assessment of Immune Potency of SARS-CoV-2 VLP Vaccine in Mice, Enhanced Through Different Adjuvants and Liposome Complexation | |
| Chen et al. | Immunogenicity, Efficacy and Twelve-Month Storage Stability Studies of a Lyophilized Rabies mRNA Vaccine. Vaccines 2025, 13, 743 | |
| HK40122702A (en) | Intranasal vaccines and therapeutics for respiratory diseases | |
| Leong et al. | NTX250: A Modular mRNA-Based Immunotherapy Platform for HPV-Associated Cancers with Broad Applicability | |
| Fu et al. | IL-7 promotes mRNA vaccine-induced long-term immunity | |
| Brown | Development of Genetic Medicines for the Treatment and Prevention of Infectious Disease, Cancer, and Aging | |
| CN118574926A (zh) | 合理设计的单轮感染性病毒及其使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241101 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241101 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250825 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20251022 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20260511 |